Skip to content

Dexmedetomidine in Attenuation of Haemodynamic Response to Laryngoscopy in Controlled Hypertensive Patients

Role of Intravenous Dexmedetomidine in Attenuation of Hemodynamic Response to Laryngoscopy in Controlled Hypertensive Patients: A Prospective Randomised Double-Blind Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07557680
Enrollment
70
Registered
2026-04-29
Start date
2025-01-01
Completion date
2025-06-30
Last updated
2026-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Hemodynamic Response, Hypertension

Keywords

Hypertension, Stress response, Dexmedetomidine, Direct Laryngoscopy

Brief summary

This randomized control trial, which was carried out at Sindh Institute of Urology and Transplantation (SIUT), used a non-probability consecutive sampling technique for six months from January 1, 2025, to June 30, 2025.

Detailed description

A prospective, randomized, blinded, placebo-controlled clinical trial was conducted in the Sindh Institute of Urology and Transplantation (SIUT) Department of Anesthesiology. Before their involvement in the study, all individuals provided written informed consent. In order to account for potential dropouts, 35 participants were recruited in each group (the dexmedetomidine group and the control group), for a total of 70 participants. The method of non-probability consecutive sampling was utilized to select the eligible participants until the necessary sample size was obtained. Randomization was done using computer-generated sequences, while allocation concealment was done using opaque, sealed envelopes. The sample was split into a 1:1 control group and a dexmedetomidine group at random. Dexmedetomidine: 0.5 μg/kg of dexmedetomidine was prepared in 20 mL of 0.9% saline to infuse in the dexmedetomidine group. Placebo: 20 mL of 0.9% saline was used to infuse in the control group. The study infusion was assigned and administered within ten minutes of the anesthetic induction, following baseline monitoring and intravenous cannulation. Non-invasive blood pressure, pulse oximetry, three-lead ECG, end-tidal CO₂ (EtCO₂), and capnography were all part of routine monitoring. Anesthesia was induced with lignocaine. After three minutes of mask ventilation, the experienced anesthesiologists carried out direct laryngoscopy and tracheal intubation, and the laryngoscopy time was measured. Anesthesia was supported by isoflurane in a mixture of air and oxygen, and mechanical ventilation was supported to keep EtCO₂ at 35 to 40 mmHg. Bradycardia (less than 50 beats per minute) was corrected using atropine 0.5 mg intravenously, and hypotension was corrected with ephedrine 5 mg intravenously.

Interventions

DRUGDexmedetomidine

Dexmedetomidine (0.5 mcg/kg) diluted in 20 mLs of normal saline was administered intravenously using a syringe pump over 10 min.

OTHERNormal Saline

20 mLs of normal saline was administered intravenously using a syringe pump over 10 min.

Sponsors

Sindh Institute of Urology and Transplantation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

The sample was split into a 1:1 control group and a dexmedetomidine group at random. The dexmedetomidine group was infused with 0.5 μg/kg of dexmedetomidine in 20 mL of 0.9% saline. Whereas the control group was infused with 20 mL of 0.9% saline only. The preparation of the study infusions was carried out by an independent anaesthesiologist who was not engaged in the care or data collection of the patients. The participants, as well as the outcome assessors, were blinded regarding grouping. The study infusion was assigned and administered within ten minutes of the anaesthetic induction, following baseline monitoring and intravenous cannulation. Non-invasive blood pressure, pulse oximetry, three-lead ECG, end-tidal CO₂ (EtCO₂), and capnography were all part of routine monitoring.

Intervention model description

The method of non-probability consecutive sampling was utilized to select the eligible participants until the necessary sample size was obtained. The patients who were aged 20-70 years, who had controlled hypertension under the antihypertensive therapy, and who were ASA II were included14. Hypertension was recognized as a measurement of systolic blood pressure surpassing 140 mmHg or diastolic blood pressure over 90 mmHg, which was sufficiently controlled with medication. Exclusion criteria included severe cardiac arrhythmias, a history of myocardial infarction, severe valvular heart disease, uncontrolled diabetes, severe hepatic or renal dysfunction, beta-blocker use, pregnancy, a known allergy to study medications, and an anticipated difficult airway. Randomization was done using computer-generated sequences, while allocation concealment was done using opaque, sealed envelopes. The sample was split into a 1:1 control group and a dexmedetomidine group at random.

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Ages from 18 to 65 years. * Patients with a known case of controlled hypertension. * ASA II * Elective surgical procedure under general anaesthesia. * Mallampati grades 1 and 2. * Patients consenting to participate in this study

Exclusion criteria

* Patients with an anticipated difficult intubation. * Those requiring more than 15 seconds or more than one attempt or use of a bougie during laryngoscopy. * A patient who has not taken an antihypertensive drug early morning on the day of surgery. * Patients with a history of allergy to drugs being used. * Patients with uncontrolled hypertension (BP \> 140/90 mmHg). * History of bradycardia (resting heart rate \< 60 bpm). * Patients on beta blockers if resting heart rate \< 60 bpm. * History of valvular heart disease, uncontrolled diabetes, liver, or kidney disease. * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Heart Rate via 3 lead ECG monitorPerioperativeIn the operating room, the ASA standard monitoring was attached to the patient.
Systolic Blood Pressure measured via a non invasive blood pressure devicePerioperativeIn the operating room holding area, the ASA standard monitoring was attached to the patient, which includes a non-invasive blood pressure monitor (cuff size was used according to the patient's weight and height).
Diastolic Blood Pressure measured via a non invasive blood pressure devicePerioperativeIn the operating room, the ASA standard monitoring was attached to the patient, which includes a non-invasive blood pressure monitor (cuff size was used according to the patient's weight and height).
Mean Blood Pressure measured via a non-invasive blood pressure devicePerioperativeIn the operating room, the ASA standard monitoring was attached to the patient, which includes a non-invasive blood pressure monitor (cuff size was used according to the patient's weight and height).

Secondary

MeasureTime frameDescription
Bradycardia (heart rate less than 60 beats per minute)PerioperativeMeasured by an ECG monitor
HypotensionPerioperativeSystolic blood pressure less than 90 mmHg measured via a non-invasive blood pressure device

Countries

Pakistan

Contacts

PRINCIPAL_INVESTIGATORSyed M Abbas

Sindh Institute of Urology and Transplantation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 30, 2026